Prolaris Leads to Active Surveillance

October 31, 2018

1 in 40 patients diagnosed with prostate cancer will die from the disease.

Most of these patients diagnosed however, have been radically treated with radiation therapy or surgery. Unfortunately, these aggressive treatments come with many side effects which have a significant impact on the quality of life.

Since each individual patient’s cancer is different, it’s important to understand just how aggressive each unique patient’s cancer truly is. Luckily, the Prolaris test provides physicians and patients with that information to help make better informed decisions about treatment.

Understanding the aggressiveness of an individual’s prostate cancer often puts people at ease knowing the chance of their cancer progressing, is low.

Watch the video above to find out more about how Myriad supports prostate cancer survivors.